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Research Pilot Award Program (RPAP) sees success over several years since its inception

Paul Visintainer, PhD, oversees
the RPAP program.

The Research Pilot
Award Program (RPAP) is
an internal grants program
designed to help UMMSBaystate faculty test
study designs and collect
preliminary data to support
a larger external grant
application. The program
is underwritten completely with indirect funds
obtained through existing
federal grant awards
Beginning in the summer
of 2016, the program has
solicited applications and
funded proposals each
year. The application

process is competitive,
and funding depends on
the number and quality of
the applications, as well
as the availability of funds.
A committee of experienced clinical researchers reviews and scores
each application on three
criteria: the experience
of the investigator with
conducting research, the
feasibility and fundability
of the proposed study,
and whether the study is
consistent with the mission
of Baystate.
To date, the program has

funded 16 clinical investigators across several departments and disciplines. The
studies that have been
completed have supported
four grant applications,
two published papers, and
three further manuscripts
in preparation. Moreover,
these pilot studies have
provided the investigators
critical information about
their protocols – patient
eligibility, recruitment, subject compliance, measurement of variables, required
staffing, collaborations
with external agencies, as

examples. As these studies
illustrate, it is difficult to
overstate the importance
of pilot studies: they tell
us what works – and
what doesn’t – enabling
us to correct and modify
our approaches, thereby
producing more competitive, feasible, and clinicallyrelevant applications.
In this issue, we consider
six RPAP studies that have
been completed thus far.
Future issues of The Innovator will highlight ongoing
and new RPAP studies and
their principal investigators.

A Pilot Randomized Controlled Study of Non-Invasive Ventilatory Support for Acute Hypoxemic
Respiratory Failure: High Flow Nasal Oxygen vs. Helmet-Non-Invasive vs. Mask-Non-Invasive
Ventilation
Mark Tidswell, MD, Associate Professor of Medicine at UMass Medical School-Baystate; Associate Professor of Medicine,
Tufts University School of Medicine
Non-invasive ventilatory
modes such as noninvasive positive pressure
ventilation (NIPPV) and
high-flow nasal cannula
oxygen (HFNO) improve
gas exchange, reverse
hypoxemia, and may
prevent intubation and
the risks associated with
invasive mechanical
ventilation including need
for sedation, delirium, lung
injury, and nosocomial
pneumonia.
Traditionally, NIPPV
is delivered through a

face-mask, but patient
intolerance and air leaks
are frequent with maskNIPPV. More recently,
delivery of NIPPV through
a helmet interface resulted
in better tolerance than
the face-mask and allowed
the use of higher levels of
positive pressure ventilation (PEEP).
No studies have yet
compared all three modalities (HFNO, mask-NIPPV
and helmet-NIPPV) in a
population of patients with
hypoxemic respiratory

failure. We proposed a
pilot randomized controlled trial to assess the
effect of HFNO and helmet-NIPPV on intubation
rate among patients with
AHRF. These rates were
compared with historical
data obtained from the
literature for mask-NIPPV
intubation rates in similar
population. Our main
objective was to collect
feasibility data on helmet
NIPPV and other clinical
elements in preparation
for a full-scale randomized

trial based on findings of
this pilot study.
The project was
terminated early because
of difficulty achieving
recruitment targets. What
we learned is that the
selection criteria were
likely too rigid, which
restricted the size of the
potential patient pool and
increased the time and
effort required for patient
screening. Finally, patient
participation was lower
than expected.

Research Question? Call the Office of Research at our central number: 413-794-3391

Mark Tidswell, MD
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Novel Scoring to Increase Sensitivity of
Polysomnography (PSG) for Clinical Significant
Obstructive Sleep Disordered Breathing
Karin Johnson, MD, Vice Chair for Academic Affairs and
Associate Professor, Department of Neurology, UMass Medical
School-Baystate
My RPAP project led
to two publications so
far: “Cardiovascular and
Somatic comorbidities
and sleep measures
using three hypopnea
criteria in mild sleep
disordered breathing:
sex, age and body mass
index differences in
a retrospective sleep
cohort” in Journal of
Clinical Sleep Medicine2
and “Flow Limitation/
Obstruction With Recovery Breath (FLOW) Event
For Improved Scoring of
Mild Obstructive Sleep
Apnea without Electroencephalography” in

Karin Johnson, MD

Sleep Medicine1.
Overall, the RPAP
provided me with the
connections within the
outstanding research,

IRB, and epidemiology
teams at Baystate and
provided a foundation
that has facilitated other
research projects. I was
able to be a research
mentor for several
summer students,
college students,
and PURCH medical
students. This included
becoming site PI for an
investigational drug for
Idiopathic Hypersomnia
patients and research
on readmission rates in
inpatients undergoing
sleep studies as well as
the impact of COVID-19
on sleep laboratories.

1: Johnson KG, Johnson DC, Thomas RJ, Feldmann E, Lindenauer PK, Visintainer P, Kryger MH. Flow
limitation/obstruction with recovery breath (FLOW) event for improved scoring of mild obstructive sleep
apnea without electroencephalography. Sleep Med. 2020 Mar;67:249-255.
2: Johnson KG, Johnson DC, Thomas RJ, Rastegar V, Visintainer P. Cardiovascular and somatic
comorbidities and sleep measures using three hypopnea criteria in mild obstructive sleep-disordered
breathing: sex, age, and body mass index differences in a retrospective sleep clinic cohort. J Clin Sleep
Med. 2020 Oct 15;16(10):1683-1691.

Improving Patient-Centered Outcomes for
Adolescents with Depressive Illness through the
Massachusetts Child Psychiatry Access Project
(MCPAP)
Bruce Waslick, MD, Associate Professor of Psychiatry, UMass
Medical School-Baystate
There is increasing
evidence that various
models of primary care
supports and enhancements are effective in
increasing detection
of depressive illness in
adolescents and facilitating families’ access to
effective care services.
The Massachusetts
Child Psychiatry Access
Project (MCPAP) model
of primary care practice
support was established
as a state-wide system
of care enhancement in
Massachusetts in 2004
and has been replicated
and widely disseminated
in over 25 other states
and regions. While
the use of MCPAP by
primary care providers improves access

Bruce Waslick, MD

to mental health care
for their patients, the
program has not been
evaluated in terms of
improving mental health
outcomes compared
with interventions such
as screening/referral
alone. Thus, the overall
aim of this proposal
was to evaluate the

effectiveness of the
MCPAP model in the
evaluation and treatment
of adolescent depression in primary care. The
MCPAP-supported model
employs screening,
assessment, intervention
and referral support in
primary care pediatric
practices.
The project was
terminated in its first
year due to several
unanticipated obstacles,
including inability to
recruit and enroll primary
care practices in a timely
fashion and disparate
medical record systems,
which made collecting
comparable data across
practices challenging
and demanding on time
and effort.

Engaging School Nurses in Diabetes
Care Team to Improve Diabetes SelfManagement Skills, Adherence, and
Glycemic Control in Children with T1DM
Ksenia N. Tonyushkina, MD, Pediatric Endocrinologist
and Assistant Professor of Pediatrics, UMass Medical
School-Baystate
The overall objective
of this pilot proposal was
to evaluate the feasibility
of monthly insulin dose
adjustments for students with
T1DM through collaboration
between pediatric diabetes
clinic and school nurses and
impact of this intervention
on diabetes control. Specifically, the goals were to
evaluate the changes in A1C,
diabetes self-management
(DSM) behaviors in children
with T1DM and their families,
and to determine patient
acceptance and satisfaction
with this intervention.
We showed that school
nurses could be engaged
in a diabetes care team
and model diabetes care at
school with on-going support and education by the

Ksenia N. Tonyushkina, MD

diabetes clinic team. We also
found a trend toward better
diabetes control during the
school year vs. summer. The
study suggested that involvement of school nurses could
improve care of high-risk
students in need of intensive
diabetes care coordination
and supervision.

Exercise Prescription in Cardiac
Rehabilitation: A Pilot Randomized
Controlled Trial
Quinn R. Pack, MD, MSc, Associate Professor of
Medicine, UMass Medical School-Baystate; Adjunct
Associate Professor of Medicine, Tufts University
School of Medicine
As of October 2020, our
RPAP was in the final stages
of completion. We had 48
total patients enroll and complete baseline stress tests,
of which 4 dropped out, 20
discontinued the protocol
prematurely due to COVID,
and 24 completed the full
protocol. We were successful
in implementing our protocols. Patients randomized
to a target heart rate range
increased their exercise
intensity by about 5 beats
per minute and increased
their exercise capacity by
an additional 1 MET. Patient
satisfaction was high.
In June 2020, Dr. Pack
utilized these pilot findings to
apply for a Physician-Scientist Early Stage Investigator
R01 grant from the NHBLI. In
August 2020, Meredith Shea
defended her dissertation

Quinn R. Pack, MD, MSc

and was awarded a PhD from
Springfield College. In October 2020, she presented this
data at the national meeting
of the American Association of Cardiovascular and
Pulmonary Rehabilitation and
won the Beginning Investigator Award. Three manuscripts
are planned and are in various stages of submission.

Evaluation of AntiGD2-PolyMPC−Dox Prodrugs in a
Neuroblastoma Tumor Model
Michael Tirabassi, MD, Assistant Professor of Surgery, UMass Medical
School-Baystate
The use of polymerprodrug strategies has
demonstrated many
advantages for enhanced
chemotherapeutic drug
delivery with improved
tumor targeting, reduced
adverse effects, and
superior efficacy. These
agents achieve these
benefits by covalently
binding the small chemotherapeutic molecule to
a bulky polymer, preventing the extravasation of
the drug from systemic
vascular endothelium
until it reaches the “leaky”
tumor bed capillaries. This mechanism
(known as the enhanced
permeation and retention (EPR) effect7-9),
passively selects for the
desired site of action and
promotes drug exposure
over a longer time-frame,
resulting in less frequent
dosing requirements.
Polymer prodrugs thus
permit administration of a
higher maximum tolerated

Michael Tirabassi, MD

dose (MTD), enabling
delivery of more drug
to the cancer target
while reducing off-target
side-effects.
The Schneider lab at
PVLSI has shown that
polymethacryloyloxyethyl phosphorylcholine
(polyMPC) in vivo are
safe and efficacious in
toxicity and immunogenicity experiments in mice.
We proposed to combine
the benefits of anti-GD2
immunotherapy with
the polyMPC prodrug
platform. Success in this
project would represent

a potential breakthrough
in neuroblastoma by
decreasing the toxic
effects, as well as the
frequency and duration of
chemotherapy, improving
their quality of life during
therapy, in addition to
their survival. This is a
cutting-edge approach
not only for the treatment
of neuroblastoma, but for
that of all cancer types.
While success in this
project would represent
a potential breakthrough
in neuroblastoma
therapy, the project was
hampered by technical hurdle of attaching
the chemotherapeutic
molecule to the polymer.
Consequently, the project
was halted. As therapeutic polymer formulations
advance, this project may
be reconsidered.
Dr. Tirabassi was also
a past participant in the
Research Faculty Development Program (RFDP).

News from UMass CCTS
THE NATIONAL
COVID COHORT
COLLABORATIVE (N3C)
The National COVID
Cohort Collaborative
(N3C) Data Enclave is
now open to scientists
looking for evidencebased answers to
COVID-19 research
questions. This
centralized and secure
national data analytics
platform is for COVID19 research, including
studying potential risk
factors, protective
factors and long-term
health consequences, as
the pandemic continues
to evolve. Its data and
analytics capabilities will
grow over time.
CCTS SPARK
PROGRAM
Rolling application
deadline. This
program’s priorities

The Innovator | 3

Closing RPAP statement from
Paul Visintainer, PhD
A senior military
commander once rued,
“No battle plan survives
contact with the enemy.”
The same may be said
of research. Ideas and
protocols may appear
elegant and feasible on
paper, only to fall short
once they are attempted
in practice. Consequently,
the efforts above are not
without their obstacles.
For some of the
studies, the challenges
proved too substantial
to overcome, given the
available time and funding. Technical barriers at
the basic science level
or inability to identify

and recruit a sufficient
number eligible patients
led to early termination of
studies. It is important to
recognize, however, that
this pilot phase is where
protocols are evaluated
and refined.
As William Whewell, a
historian and philosopher
noted, “Every failure is a
step to success”. This is
the goal of the RPAP – to
give clinicians who are
committed to a career in
research an opportunity
to present their ideas and
refined their approaches
in an effort to develop a
robust research project.

Kudos: Laura Sorci appointed to
national committe with NRG Oncology
Laura Sorci, Sr. Clinical
Research Coordinator,
was recently appointed
as a member of the CRA
Subcommittee of NRG
Oncology as of January
2021. Her appointment
will last for 3 years. She
is assigned to the Quality
Control working group
within the organization.

This role will be a great
experience for her and
Baystate Health as an
institution.
Her appointment
reflects her expertise and
dedication to participating
in NRG Oncology cancer
clinical trials.
Congratulations, Laura!

Select Recent Awards
are to support studies
that impact clinical
care and research
methodologies, support
students/trainees,
and provide access
to funds to generate
pilot and preliminary
data for external grant
submissions. For
more information, visit
umassmed.edu/ccts/
funding/spark-program.

system. Visit the
following link for more
information: umassmed.
edu/ccts/funding/
small-conference-grants.

CCTS SMALL
CONFERENCE GRANTS
Rolling application
deadline. This
funding facilitates the
development of facultyto-faculty networks
within the University

QUESTIONS?
Contact Nate Hafer,
PhD at 508-856-2511,
by emailing Nathaniel.
Hafer@umassmed.edu,
or visit umassmed.edu/
CCTS.

K-CLUB: Dr. Mihaela
Stefan has just been
added as a co-leader.
Baystate faculty are
encouraged to join!
umassmed.edu/ccts/
education/k-club

OB/GYN
NEENA QASBA, MD, Access,
Contraceptive Coverage,
Expected Supply in our State,
ACCESS Study Part 3, Baystate
Health, Inc., RPAP.
CHILD PSYCH
BARRY SARVET, MD, MCPAP
Medical Director Jul-Dec 2020,
Beacon Health Options.
EMERGENCY
HOWARD SMITHLINE, MD,
PReventing Emerging infections
through Vaccine EffectiveNess Testing—COVID (Project
PREVENT), University of CA/LA
Olive View, CDC.
CRITICAL CARE
JAY STEINGRUB, MD, Surveillance of Respiratory Viruses in
the Critically Ill: 2020-2021 IVY
Network Surveillance Study,
Vanderbilt University Med. Ctr.,
CDC.

JAY STEINGRUB, MD, Phase
2, Randomized, Double-Blind,
Placebo-Controlled Study of the
Effect of Anti-CD14 Treatment
in Hospitalized Patients with
COVID-19 (DAIT-COVID-19-003),
Benaroya Research Inst. (BRI),
Nat. Inst. Allergy Infec. Disease.
MARK TIDSWELL, MD, A Multicenter, Adaptive, randomized
Controlled Platform Trial of Safety
and Efficacy of Antithrombotic
Strategies in Hospitalized Adults
with COVID-19, NYU School of
Medicine, Nat. Heart Lung Blood
Inst.
PEDIATRICS
MANDI SUMMERS, FY21 CPS
Administration, MA Exec. Office
Public Safety, US Dept. of
Highway Safety.
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Remembering Alan Schneyer, PhD, friend and colleague
Alan Schneyer was a
vital part of the community at Baystate Medical
Center, and therefore,
his death on November
18th, 2020 has impacted
many of us. He was a
researcher, a teacher, an
entrepreneur and, most
valued, he was a friend
and colleague to many of
us. Alan was a frequent
guest for Grand Rounds in
the Division of Endocrinology at Baystate Medical
Center, invited lecturer
at UMass Amherst and a
guest lecturer in courses.
He was a collaborator in
science locally as well as
nationally and internationally. Alan’s obituary can
be found at bit.ly/3grYZxx.
His life is a reminder of
what we have all lost, and
especially his wife, Elissa
Brown, and children, Jon
and Becca.

Sciences Institute in 2007.
Alan was a fixture in the
research community of
Western Massachusetts
with faculty appointments
at both Baystate Medical
Center and the University
of Massachusetts-Amherst.
The move to western Massachusetts was stimulated
by his creation of a mouse
model for polycystic ovarian disease. But his work
demonstrated unexpected
effects of follistatin-like
proteins on the function
of pancreatic beta cells
and their role in diabetes.
This result caused him
to shift the focus of his
research to diabetes. He
could see the potential for
a completely new strategy
to manage diabetes. This
was to devise therapeutics
to restore the function of
the pancreatic beta cells
rather than simply provide
insulin by daily injections
to patients. A grand idea,
but he was unwilling to be
satisfied with simply an
idea and he committed
himself to the task of building this new therapy.
To support new innovations in diabetes care,

A Life in Science
After more than 20
years as a researcher at
Massachusetts General
Hospital in Reproductive Endocrinology, Alan
was recruited to join
the Pioneer Valley Life

be found at the company’s
website (fairbankspharma.
com/author/aschneyer).

Dr. Alan Schneyer, pictured
above, passed away on
November 18, 2020.

Alan obtained grants from
the Juvenile Diabetes
Research Foundation and
the National Institutes
of Health supporting
his work. But to drive
this work forward to a
viable therapeutic would
require a more focused
approach. Therefore, in
2014 he started Fairbanks
Pharmaceuticals, Inc. The
company was awarded a
patent for their therapeutic
in fall 2020. Fairbanks
continues with this work
and will provide a legacy
that most of us aspire to.
Some of Alan’s posts can

A Friend and Colleague
We remember Alan as
the indomitable optimist,
an individual who could
see opportunities as
well as the hurdles. He
provided support for
those around him. He
was recognized for his
patience as a teacher. The
success of his students
and staff reflect his ability
to both communicate
and stimulate a passion
for research. For us, Alan
represented the best of
science and the effort to
use science to improve
the lives of people.
That included the joy of
discovery, the challenge
of wrestling with technical problems as well as
developing new therapies
and the relentless desire
to never give up on a
dream. Throughout all
of this, his compassion
was ever-present. He
also brought joy when
we talked about cycling,
watching an ultimate
tournament or discussing

a weekend with his family.
Alan was much more than
a colleague. Though he is
sorely missed, Alan leaves
us with many more joys for
having known and worked
with him.
Since Dr. Schneyer’s
death, the work of
Fairbanks Pharmaceuticals has been continued
through the leadership of
his wife, Elissa Schneyer,
and scientific guidance of
his collaborator Dr. Melissa
Brown together with the
staff at Fairbanks Pharmaceuticals. A manuscript
by the group has been
accepted for publication
in Endocrinology and
will be available online
shortly. The title is “FSTL3
Neutralizing Antibodies
Enhance Glucose-Responsive Insulin Secretion In
Dysfunctional Male Mouse
And Human Islets”. This
work demonstrates the
efficacy of a new therapy
for treatment of diabetes
that serves to preserve the
function of pancreatic beta
cells, and thus, delaying
the need for replacement
of insulin.

News from Tufts CTSI

Scholarships Available for
Health Economics & Outcomes Research (HEOR)
Certificate Program
Baystate Health
employees may be
eligible for a 40% scholarship to the new Certificate Program in Health
Economics and Outcomes
Research (HEOR)!
The HEOR Program
is offered by the Tufts
University Graduate
School of Biomedical
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Sciences (GSBS) Clinical
and Translational Science
(CTS) Graduate Program,
and is co-directed by
David Kent, MD, CM, MSc,
Director of the CTS Graduate Program, and Peter
Neumann, ScD, Director of
the Center for Evaluation
of Value and Risk (CEVR).
Individuals seeking an
introduction to HEOR,
including clinicians and
other health care professionals, professionals in
the pharmaceutical and
biotechnology industry,
graduate degree holders,
and graduate degree
students, are encouraged
to apply.
The Program is

designed to accommodate
the schedules of learners
who are already immersed
in professional careers or
other training programs.
To apply for a scholarship,
please email Elizabeth
Leary, PhD, Graduate
Program Manager, at
ewiltrout@tuftsmedicalcenter.org.
Introducing Tufts CTSI I
LEARN!
Tufts Clinical and Translational Science Institute
(CTSI) recently launched
Tufts CTSI I LEARN (ilearn.
tuftsctsi.org), a modern,
interactive online learning
portal offering non-degree
professional education

and training opportunities
in clinical and translational
research.
Tufts CTSI I LEARN
includes live-streamed,
blended synchronous and
asynchronous courses,
self-paced courses,
and recorded seminars,
workshops, and trainings
to support the professional
development of research
stakeholders including
investigators, coordinators,
community members, and
research participants. The
user-friendly platform was
built in the D2L Brightspace learning management system.
Anyone interested
in exploring Tufts CTSI

We are interested in ensuring that Baystate employees and patients (and their families) are aware of the important
research that goes on at Baystate and how it contributes to better patient care. The Innovator welcomes feedback
and story ideas. Contact Allison Billeter at allison.billeter@baystatehealth.org to submit yours.

I LEARN should create
a free user account to
access more than 100
learning opportunities.
Users of the original
I LEARN platform will
need to register for new
accounts. With a Tufts
CTSI I LEARN account,
users can keep track of
their courses and earn
certificates of course
completion. Questions?
Please email training@
tuftsctsi.org.

